2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: MS2

Poster-Disease-modifying Therapy

October 25, 2021

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data

Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models

Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy

Background: The treatment landscape for multiple sclerosis (MS) continues to evolve and many disease-modifying therapies (DMTs) with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies

Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...

Read More →

Poster-Complementary and Alternative Therapies

October 25, 2021

Remote Art Therapy Activities Proposal during a COVID-19 Pandemic in Multiple Sclerosis

Background: SARS-CoV-2 infection poses a potential threat to people with autoimmune disorders, including multiple sclerosis (MS).With the...

Read More →

Platform-Rehabilitation

October 25, 2021

Frequency and Characteristics of Falls in People Living with and without Multiple Sclerosis during the COVID-19 Pandemic: An Online Survey

Background: Public health responses to Coronavirus Disease 2019 (COVID-19) including lockdowns may negatively impact physical and mental...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC